Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4589105 | 0.82 | LMNA (0.49) | LMNA | |
| SCHEMBL1797557 | 0.81 | OPRD1 (0.45) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL1797560 | 0.81 | OPRD1 (0.45) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL3515953 | 0.81 | OPRD1 (0.45) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL1797148 | 0.80 | CHRNB4 (0.50) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL1794388 | 0.80 | CHRNB4 (0.50) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL1797151 | 0.80 | CHRNB4 (0.50) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL1795410 | 0.80 | CHRNB4 (0.50) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL1795653 | 0.80 | CHRNB4 (0.50) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL11319218 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326722-B2 | N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives, their preparation and their application in therapy | SANOFI-AVENTIS (FR) | 2008-02-05 | — | — | US | disclosed |
| US-20070197601-A1 | Use of N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives in therapy | SANOFI-AVENTIS (FR) | 2007-08-23 | — | — | US | disclosed |
| EP-1499589-B1 | DERIVATIVES OF N-PHENYL(PIPERIDIN-2-YL)METHYL BENZAMIDE, THE PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2007-05-02 | — | — | EP | disclosed |
| US-20050159450-A1 | Derivative of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2005-07-21 | — | — | US | disclosed |
| EP-1499589-A1 | DERIVATIVES OF N-PHENYL(PIPERIDIN-2-YL)METHYL BENZAMIDE, THE PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003089411-A1 | DERIVATIVES OF N-[PHENYL(PIPERIDIN-2-YL)METHYL]BENZAMIDE, THE PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197601-A1 | Use of N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives in therapy | SLC1A2, SLC1A1, SLC1A5 | OPRM1 1288/4885OPRD1 1342/4885OPRK1 1701/4885 |
| US-20050159450-A1 | Derivative of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics | NPR3, NR4A3, PRMT3 | OPRM1 66/4885OPRD1 99/4885OPRK1 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.